<DOC>
	<DOCNO>NCT02675803</DOCNO>
	<brief_summary>This study investigate safety tolerability VAY736 administer single ascending dos intravenous infusion , subcutaneous injection repeat subcutaneous injection rheumatoid arthritis patient .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics Study VAY736 Rheumatoid Arthritis Patients</brief_title>
	<detailed_description>This study three sequential part investigate safety tolerability VAY736 administer single ascending dos intravenous infusion ( Part 1 ) , single ascending dos subcutaneous injection ( Part 2 ) , repeat subcutaneous injection fix dos ( Part 3 ) , respectively , rheumatoid arthritis patient . Part 1 double blind , placebo control , 11 cohort . Part 2 open-label study 2 dosing cohort . Part 3 open-label study 1 fixed-dose cohort .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Active disease despite methotrexate treatment 5 20 mg/week Parts 1 2 ; methotrexate treatment 5 20 mg/week Part 3 Fulfilled 2010 American College Rheumatolody ( ACR ) /European League Against Rheumatism ( EULAR ) classification criterion rheumatoid arthritis Part 1 Part 2 . For Part 3 , fulfil 2010 American College Rheumatolody ( ACR ) / ) /European League Against Rheumatism ( EULAR ) classification criterion or/and 1987 American College Rheumatolody ( ACR ) classification criterion rheumatoid arthritis ; Methotrexate ≥ 16 week , stable dose ≥ 8 week Previous treatment B celldepleting biologic agent . Autoimmune disease RA except concurrent Sjogren 's syndrome Adult juvenile rheumatoid arthritis ARA functional class IV disease ACR Revised Steinbrocker Classification</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
</DOC>